Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 31;18(S1):281-290.
doi: 10.4142/jvs.2017.18.S1.281.

Development and Trial of Vaccines Against Brucella

Affiliations
Free PMC article
Review

Development and Trial of Vaccines Against Brucella

Jonathan Lalsiamthara et al. J Vet Sci. .
Free PMC article

Abstract

The search for ideal brucellosis vaccines remains active today. Currently, no licensed human or canine anti-brucellosis vaccines are available. In bovines, the most successful vaccine (S19) is only used in calves, as adult vaccination results in orchitis in male, prolonged infection, and possible abortion complications in pregnant female cattle. Another widely deployed vaccine (RB51) has a low protective efficacy. An ideal vaccine should exhibit a safe profile as well as enhance protective efficacy. However, currently available vaccines exhibit one or more major drawbacks. Smooth live attenuated vaccines suffer shortcomings such as residual virulence and serodiagnostic interference. Inactivated vaccines, in general, confer relatively low levels of protection. Recent developments to improve brucellosis vaccines include generation of knockout mutants by targeting genes involved in metabolism, virulence, and the lipopolysaccharide synthesis pathway, as well as generation of DNA vaccines, mucosal vaccines, and live vectored vaccines, have all produced varying degrees of success. Herein, we briefly review the bacteriology, pathogenesis, immunological implications, candidate vaccines, vaccinations, and models related to Brucella.

Keywords: Brucella; animal models; brucellosis; vaccines.

Conflict of interest statement

Conflict of Interest: The authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

References

    1. Alcantara RB, Read RD, Valderas MW, Brown TD, Roop RM., 2nd Intact purine biosynthesis pathways are required for wild-type virulence of Brucella abortus 2308 in the BALB/c mouse model. Infect Immun. 2004;72:4911–4917. - PMC - PubMed
    1. Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K, Letesson JJ. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun. 2001;69:4816–4822. - PMC - PubMed
    1. Almirón M, Martínez M, Sanjuan N, Ugalde RA. Ferrochelatase is present in Brucella abortus and is critical for its intracellular survival and virulence. Infect Immun. 2001;69:6225–6230. - PMC - PubMed
    1. Alton GG, Jones LM, Angus RD, Verger JM. Techniques for the brucellosis laboratory. Paris: Institut National de la Recherche Agronomique; 1988.
    1. Anderson TD, Cheville NF. Ultrastructural morphometric analysis of Brucella abortus-infected trophoblasts in experimental placentitis. Bacterial replication occurs in rough endoplasmic reticulum. Am J Pathol. 1986;124:226–237. - PMC - PubMed
Feedback